Kamada (NASDAQ:KMDA) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Kamada (NASDAQ:KMDA) from a strong-buy rating to a buy rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “buy (b-)” rating on shares of Kamada in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $13.00.

Kamada Price Performance

Kamada stock traded down $0.09 during trading hours on Friday, hitting $6.99. The stock had a trading volume of 61,456 shares, compared to its average volume of 113,145. Kamada has a 1-year low of $5.54 and a 1-year high of $9.15. The stock has a market capitalization of $401.96 million, a price-to-earnings ratio of 20.56, a PEG ratio of 0.70 and a beta of 0.81. The stock’s fifty day moving average is $6.89 and its two-hundred day moving average is $7.09.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Kamada had a return on equity of 7.41% and a net margin of 11.22%.The business had revenue of $47.01 million during the quarter, compared to analysts’ expectations of $154.21 million. Kamada has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Kamada will post 0.23 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. ARK Investment Management LLC acquired a new stake in Kamada during the second quarter worth about $1,972,000. Jane Street Group LLC purchased a new stake in shares of Kamada during the 1st quarter worth about $582,000. Goldman Sachs Group Inc. acquired a new stake in Kamada during the 1st quarter worth approximately $497,000. Essex Investment Management Co. LLC raised its holdings in Kamada by 22.4% in the third quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock valued at $2,751,000 after buying an additional 72,602 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Kamada during the second quarter valued at approximately $472,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.